Radiotherapy after complete resection and neoadjuvant chemotherapy failed to significantly improve 3-year DFS among certain patients with non-small cell lung cancer, according to study results presented during ESMO Virtual Congress 2020.

The addition of abemaciclib to endocrine therapy significantly extended invasive DFS for patients with high-risk hormone receptor-positive, HER2-negative breast cancer, according to findings presented during ESMO Virtual Congress 2020.

Adjuvant osimertinib induced clinically meaningful reductions in central nervous system disease recurrence and death among patients with EGFR-mutated non-small cell lung cancer, according to data presented at the ESMO Virtual Congress 2020.

In a single-center study, researchers observed no significant differences in mechanical ventilator use, hospitalization or ICU admission rates among children with COVID-19 compared with children with influenza.

Recent retina/vitreous articles discuss study results and new trials. Here are five popular items from the first half of September on Healio/OSN:

The addition of spartalizumab to dabrafenib and trametinib failed to prolong PFS among patients with BRAF-mutated advanced melanoma, according to results from the randomized phase 3 COMBI-i trial presented at ESMO Virtual Congress 2020.

Healio and Cardiology Today have compiled a list of the top-read news from the American Heart Association Hypertension Scientific Sessions.

Despite decreases in revenue and gross profit compared with the same period in 2019, Medacta reported good backlog recovery in June, July and August in its 2020 half-year financial results, according to a press release.

Sacituzumab govitecan significantly improved PFS and OS compared with single-agent chemotherapy among patients with pretreated metastatic triple-negative breast cancer, according to findings presented during ESMO Virtual Congress 2020.

Nivolumab plus cabozantinib conferred superior PFS, OS and response rates compared with sunitinib as a first-line treatment for advanced renal cell carcinoma, according to results of a phase 3 study presented at ESMO Virtual Congress 2020.